The DOI matches its Crossref record, with a small difference in title or year.
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
Abstract
Objective: This study compared the impact of 3 eicosapentaenoic acid (EPA) doses versus placebo on inflammatory biomarkers and depressive symptoms. Methods: Sixty-one unmedicated adults (75% female; 45.5 ± 13.8 years) with DSM-5 major depressive disorder (MDD), body mass index > 25 kg/m2, and plasma high-sensitivity C-reactive protein (hs-CRP) ≥ 3.0 mg/L were randomly assigned to receive EPA 1 g/d, 2 g/d, or 4 g/d or placebo for 12 weeks. Prespecified endpoints were a ≥ 0.40 effect size decrease in plasma interleukin (IL)-6, peripheral blood mononuclear cell (PBMC) cytokines, and lipopolysaccharide-stimulated tumor necrosis factor (TNF) production. Response was defined as a ≥ 50% decrease of Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30) scores. We compared outcomes for the 3 EPA doses versus placebo. Results: In 45 completers, only median PBMC TNF decreased at 2 g/d EPA. No EPA dose produced a ≥ 0.35 effect size reduction in plasma IL-6 or mitogen-stimulated TNF. Response rates for EPA 4 g/d were 64%, versus 40% for placebo (odds ratio = 2.63; Cohen d = 0.53), 38% for EPA 1 g/d, and 36% for EPA 2 g/d (all P > .05). EPA 4 g/d showed a significant correlation between percent decrease in plasma hs-CRP and IDS-C30 symptom reduction at 12 weeks (Spearman ρ = 0.691, P = .019). Conclusions: EPA 4 g/d demonstrated a medium effect size for response rates versus placebo. This dose may alleviate MDD in overweight individuals with elevated inflammatory markers, and change in hs-CRP may be correlated with clinical response. Trial Registration: ClinicalTrials.gov identifier: NCT02553915
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A dose finding study comparing 1 g, 2 g, or 4 g of omega-fatty acid capsules with a 4:1 ratio of EPA:DPA reported that high-doses (4 g/per day) were required for antidepressant efficacy in overweight or obese patients with inflammation (156).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [156]
Citations
Cites
Still being checked.
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“A dose finding study comparing 1 g, 2 g, or 4 g of omega-fatty acid capsules with a 4:1 ratio of EPA:DPA reported that high-doses (4 g/per day) were required for antidepressant efficacy in overweight or obese patients with inflammation (156).”
BackgroundUnsaturated Fatty Acids and Their Immunomodulatory Properties
Coniglio, S. J., Shumskaya, M. A., & Vassiliou, E. K. (2023) · Biology · doi:10.3390/biology12020279 · Cited by 200
Kalogerakou, T., & Αντωνιάδου, Μ. (2024) · Antioxidants · doi:10.3390/antiox13121508 · Cited by 124
Omega-3 Polyunsaturated Fatty Acids in Depression
Serefko, A., Jach, M. E., Pietraszuk, M., Świąder, M., Świąder, K., & Szopa, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168675 · Cited by 87
Du, Y., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Fan, N., Yang, X., & Ma, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1407529 · Cited by 64
Metadata
- Authors
- Mischoulon, D., Dunlop, B. W., Kinkead, B., Schettler, P. J., Lamon-Fava, S., Rakofsky, J. J., Nierenberg, A. A., Clain, A. J., Crowe, T. M., Wong, A., Felger, J. C., Sangermano, L., Ziegler, T. R., Cusin, C., Fisher, L. B., Fava, M., & Rapaport, M. H.
- Affiliations
- Massachusetts General Hospital (US)
- Emory University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2022-08-22
- Volume
- 83
- Issue
- 5
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W4292361112
- Cited by
- 56
- References
- 0
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 15 · 2023: 11 · 2022: 1
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- Funders
- National Center for Complementary and Integrative Health (UG3AT008857)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- eicosapentaenoic acid, omega-3 fatty acids, major depressive disorder, inflammation, C-reactive protein, interleukin-6, TNF-α, peripheral blood mononuclear cells, dose-response relationship, overweight, inflammatory markers, depressive symptoms
- MeSH terms
- Adult, C-Reactive Protein, Major Depressive Disorder, Docosahexaenoic Acids, Double-Blind Method, Female, Humans, Inflammation, Leukocytes, Mononuclear, Male, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Interleukin-6, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial. https://app.cochat.ai/papers/10.4088/jcp.21m14074
- The paper
- Mischoulon, D., Dunlop, B. W., Kinkead, B., Schettler, P. J., Lamon-Fava, S., Rakofsky, J. J., Nierenberg, A. A., Clain, A. J., Crowe, T. M., Wong, A., Felger, J. C., Sangermano, L., Ziegler, T. R., Cusin, C., Fisher, L. B., Fava, M., & Rapaport, M. H. (2022). Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.21m14074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.